Candel Therapeutics Balance Sheet Health
Financial Health criteria checks 0/6
Candel Therapeutics has a total shareholder equity of $-15.3M and total debt of $14.9M, which brings its debt-to-equity ratio to -97.8%. Its total assets and total liabilities are $21.5M and $36.8M respectively.
Key information
-97.8%
Debt to equity ratio
US$14.92m
Debt
| Interest coverage ratio | n/a |
| Cash | US$16.56m |
| Equity | -US$15.26m |
| Total liabilities | US$36.77m |
| Total assets | US$21.52m |
Recent financial health updates
Recent updates
Candel Therapeutics: Innovative Cancer Therapies, But Short Cash Runway
Jul 01Candel Therapeutics: CAN-2409 May Go Beyond Scope Of Targeting Pancreatic Cancer
Apr 15Candel gets European orphan drug designation for brain, spinal cord tumor treatment
Sep 15Candel Therapeutics appoints CFO, chief medical officer
Sep 07Candel Therapeutics: Next-Generation Oncolytic Viral Immunotherapies
Oct 21Financial Position Analysis
Short Term Liabilities: CADL has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: CADL has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: CADL has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: CADL's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CADL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CADL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 22.8% each year